Feb 12 (Reuters) - AnaptysBio ANAB.O:
ANAPTYS ANNOUNCES ROSNILIMAB ACHIEVED POSITIVE RESULTS IN RA PHASE 2B TRIAL AND HIGHEST EVER REPORTED CDAI LDA RESPONSE OVER 6 MONTHS
ANAPTYSBIO INC - ROSINILIMAB SAFE AND WELL TOLERATED WITH SIMILAR ADVERSE EVENT RATES VERSUS PLACEBO
ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL SIGNIFICANCE ON KEY SECONDARY ENDPOINTS AT WEEK 12
ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 12
ANAPTYSBIO INC - TOP-LINE WEEK 12 PHASE 2 ULCERATIVE COLITIS DATA FOR ROSNILIMAB EXPECTED IN Q4 2025
Source text: ID:nGNXc9Q9Gv
Further company coverage: ANAB.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。